DataMEDS AI Enters Into Agreement for Commercial Supply of Six Peptides Recommended by FDA Advisory Committee
Source · The Batesville Daily Guard
TLDR
DataMEDS AI announced that subsidiary Corexa Health entered a commercial supply agreement for six peptides. In the November 2, 2026 press release, the company says the peptides received FDA advisory committee recommendations and that Corexa Pharmacy plans to begin dispensing compounded prescriptions that month under an updated HHS enforcement discretion policy.
- 01The agreement covers BPC-157, TB-500, KPV, MOTS-c, Epitalon and Semax.
- 02The company links its distribution plans to a network of more than 6,500 independent pharmacies.
- 03DataMEDS says its Health Lives Here app will help collect and report safety data.
Why it matters Editorial
The announcement describes a planned expansion of pharmacy-compounded peptide access, with regulatory compliance claims attributed to the company.
Summary generated with AI and reviewed by an editor. The original source governs; summaries can contain errors. Information only — not medical advice. Full disclaimer.
Investing.com Canada